Irene Chicote

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer.

Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer.

Journal: Molecular cancer therapeutics

Published: May 21, 2025

Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei.

Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 28, 2023

Identifying Cell Differentiation in Colorectal Cancer.

Identifying Cell Differentiation in Colorectal Cancer.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: June 13, 2023

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer.

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer.

Journal: Journal of visualized experiments : JoVE

Published: February 27, 2023

DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype.

DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype.

Journal: Cell reports

Published: December 29, 2022

Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer.

Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer.

Journal: ESMO open

Published: December 14, 2022

The target antigen determines the mechanism of acquired resistance to T cell-based therapies.

The target antigen determines the mechanism of acquired resistance to T cell-based therapies.

Journal: Cell reports

Published: November 02, 2021

Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors.

Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors.

Journal: Nature cancer

Published: August 10, 2020

Advanced Colorectal Cancer Orthotopic Patient-Derived Xenograft Models for Cancer and Stem Cell Research.

Advanced Colorectal Cancer Orthotopic Patient-Derived Xenograft Models for Cancer and Stem Cell Research.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: July 25, 2020

Pharmacological disruption of the Notch transcription factor complex.

Pharmacological disruption of the Notch transcription factor complex.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: July 01, 2020

TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence.

TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence.

Journal: The Journal of clinical investigation

Published: July 20, 2017

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 05, 2014

Showing 1-12 of 15

Last Updated: 09/26/2026